Skip to Main Content
Table 4

Risk of combined renal outcome associated with sTNFR1

sTNFR1 (pg/mL)
No diabetes (n = 259)
Diabetes (n = 194)
HR*95% CIP valueHR*95% CIP value
Model 1 2.9 0.7–12.0 0.15 13.7 6.4–29.0 <0.001 
Model 2 0.2 0.03–1.1 0.07 5.6 1.7–18.9 0.01 
Model 3 0.2 0.03–1.0 0.05 3.8 1.1–12.8 0.03 
sTNFR1 (pg/mL)
No diabetes (n = 259)
Diabetes (n = 194)
HR*95% CIP valueHR*95% CIP value
Model 1 2.9 0.7–12.0 0.15 13.7 6.4–29.0 <0.001 
Model 2 0.2 0.03–1.1 0.07 5.6 1.7–18.9 0.01 
Model 3 0.2 0.03–1.0 0.05 3.8 1.1–12.8 0.03 

A total of 453 participants were included in the models. A total of 11 outcomes occurred in the group without diabetes and 32 outcomes occurred in the group with diabetes. Model 1 was adjusted for age and sex. Model 2 was adjusted for age, sex, and CKD-EPI eGFR. Model 3 was adjusted for age, sex, CKD-EPI eGFR, and uACR. CKD-EPI eGFR was calculated using the CKD-EPI eGFR equation based on serum creatinine without correcting for African American ethnicity.

*The HR represents the risk of developing the combined renal outcome associated with a doubling of sTNFR1 (natural logarithm) at baseline.

Close Modal

or Create an Account

Close Modal
Close Modal